Vienna, Europe, Feb 23rd, 2012 – EUCODIS Bioscience is pleased to announce the extension of its direct marketing and sales activities to North America by establishing a new representation in San Francisco, USA.
The new operation has been started with the objective to provide its US customers with more efficient sales services, and develop out licensing opportunities for our speciality enzymes and search for development partners for new proprietary technologies more effectively.
As a first step Eucodis Bioscience will be giving a presentation at BioPartnering North America, Vancouver, BC, Canada, Feb 26th- 28th, to create interest for an active collaboration or co-development agreement for further development of an innovative recombinant antibody-drug conjugation technology. The novel linker system is designed to covalently attach a recombinant antibody or antibody fragments to a therapeutic drug - through a specific enzymatic reaction.
Eucodis Bioscience will be represented in the US by James David Rozzell, PhD, an executive with 30 years of both technical and business management experience in biocatalysis. He is the founder or co-founder of several life science companies, including BioCatalytics, Inc., a leading developer and manufacturer of enzymes for pharmaceutical manufacturing and diagnostic use. David Rozzell has been on the scientific board of Eucodis Bioscience since 2008.
About Eucodis Bioscience
Founded in 2007, Eucodis is an established enzyme engineering and manufacturing company headquartered in Vienna, Austria. Eucodis Bioscience delivers high-performance enzyme solutions for highly specific applications in biopharma, fine chemicals and cosmetics industry. Our team works closely with our customers to better understand their individual needs covering the whole spectrum of biocatalytic process development up to industrial-scale manufacture of enzymes. The portfolio comprises over 50 enzymes including innovative lipases, beta-lactamases, catalases and others.
Eucodis Bioscience is a private company, backed up by institutional venture capital investors, founders, and private investors.